AFIB · As filed with the SEC
Acutus Medical cash flow statement, by fiscal year
The statement as Acutus Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Cash flows from operating activities | ||||||
| Net loss | — | — | (39,616) | (117,683) | (101,981) | (97,039) |
| Net loss | (9,547) | (81,663) | — | — | — | — |
| Less: Loss on discontinued operations | 5,011 | 69,742 | — | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
| Depreciation expense | 297 | 191 | 6,060 | 5,754 | 2,763 | 2,280 |
| AcQMap Systems converted to sales | — | 0 | 605 | 2,182 | — | — |
| Sales-type lease gain | — | 0 | (87) | 28 | — | — |
| Amortization of intangible assets | — | 0 | 420 | 640 | 457 | 250 |
| Non-cash stock-based compensation expense | 459 | 3,032 | 9,391 | 13,754 | 12,103 | 2,994 |
| Accretion of discounts on marketable securities, net | (28) | (1,428) | (24) | 1,277 | 484 | (153) |
| Amortization of debt issuance costs | 931 | 571 | 850 | 1,404 | 767 | 17,579 |
| Amortization of operating lease right-of-use assets | 730 | 683 | 649 | 496 | 684 | 637 |
| Research and development - license acquired | — | — | — | — | — | 15,000,000 |
| Impairment of property and equipment | — | — | — | — | 0 | 786,000 |
| Loss on debt extinguishment | — | 0 | 7,947 | — | — | 1,447 |
| Change in fair value of warrant liability and embedded derivative | — | — | — | — | 5,555,000 | 1,919,000 |
| Goodwill impairment | — | 0 | 12,026 | — | — | — |
| Gain on sale of business, net | (10,814) | (9,080) | 79,465 | — | — | — |
| Direct costs paid for sale of business | — | — | (4,027) | — | — | — |
| Change in fair value of warrant liability | — | — | (33) | 0 | — | — |
| Direct costs paid related to sale of business | — | 0 | — | — | — | — |
| Change in fair value of warrant liability | (215) | (2,937) | — | — | — | — |
| Loss on disposal of property and equipment | — | 0 | 825 | — | — | — |
| Change in fair value of contingent consideration | 0 | 123 | 1,053 | (3,746) | 97 | 500 |
| Changes in operating assets and liabilities: | ||||||
| Accounts receivable | (4,048) | (1,074) | (452) | (1,473) | (1,897) | (96) |
| Inventory | 2,488 | (2,484) | 3,081 | (3,872) | (3,891) | (5,421) |
| Employer retention credit receivable | — | — | (4,703) | — | — | — |
| Employer retention credit receivable | 0 | 4,703 | — | — | — | — |
| Prepaid expenses and other current assets | 48 | 656 | 2,804 | 1,133 | (3,383) | (928) |
| Other assets | — | 0 | 475 | 304 | (622) | (8) |
| Accounts payable | (1,485) | 288 | (2,852) | (871) | 2,283 | 2,111 |
| Accrued liabilities | (246) | (700) | 605 | 1,549 | 2,232 | 2,901 |
| Operating lease liabilities | — | (461) | (526) | (608) | (820) | (745) |
| Operating lease liabilities | (766) | — | — | — | — | — |
| Other long-term liabilities | 0 | (12) | (38) | 50 | — | — |
| Net cash used in operating activities - continuing operations | (17,185) | (19,850) | — | — | — | — |
| Net cash used in operating activities - discontinued operations | (14,475) | (43,268) | — | — | — | — |
| Net cash used in operating activities | (31,660) | (63,118) | (85,032) | (99,682) | (85,169) | (55,986) |
| Cash flows from investing activities | ||||||
| Proceeds from sale of business | — | — | 70,000 | — | — | — |
| Proceeds from sale of business | 18,672 | 17,000 | — | — | — | — |
| Purchases of available-for-sale marketable securities | 0 | (39,765) | (54,508) | (87,258) | (114,694) | (68,735) |
| Sales of available-for-sale marketable securities | 500 | 750 | 18,599 | 8,590 | 17,095 | — |
| Maturities of available-for-sale marketable securities | 2,750 | 82,000 | 74,642 | 107,707 | 45,000 | 14,700 |
| Purchases of property and equipment | (112) | (219) | (3,983) | (9,973) | (11,225) | (3,395) |
| Purchase of research and development license | — | — | — | — | — | (10,000,000) |
| Cash paid, net of cash acquired for the Rhythm Xience Acquisition | — | — | — | — | — | (3,000,000) |
| Net cash provided by investing activities - continuing operations | 21,810 | 59,766 | — | — | — | — |
| Net cash provided by (used in) investing activities - discontinued operations | 339 | (1,211) | — | — | — | — |
| Net cash provided by investing activities | 22,149 | 58,555 | 104,750 | 19,066 | (63,824) | (70,430) |
| Cash flows from financing activities | ||||||
| Proceeds from issuance of debt and warrants | — | — | — | — | — | 77,000,000 |
| Repayment of debt | — | — | — | — | — | (15,000,000) |
| Proceeds from issuance of common stock, net of issuance costs | — | — | 0 | — | — | — |
| Repayment of debt | (2,625) | 0 | — | — | — | — |
| Penalty fees paid for early prepayment of debt | — | 0 | (1,063) | (580) | — | (2,332) |
| Borrowing under new debt, net of fees | — | 0 | 34,825 | — | — | — |
| Payment of amendment consent fees | (225) | — | — | — | — | — |
| Payment of debt issuance costs | 0 | (490) | (626) | — | — | — |
| Proceeds from the exercise of stock options | 0 | 4 | 67 | 711 | 634 | 108 |
| Repurchase of common shares to pay employee withholding taxes | — | — | (111) | — | — | — |
| Proceeds from employee stock purchase plan | — | — | 214 | 440 | — | — |
| Proceeds from warrants exercises | — | — | — | 0 | 13 | — |
| Proceeds from issuance of common stock, net of issuance costs | — | — | — | 82,657 | 166,286 | — |
| Repurchase of common shares to pay employee withholding taxes | — | 0 | — | — | — | — |
| Proceeds from employee stock purchase plan | 0 | 25 | — | — | — | — |
| Payment of contingent consideration | 0 | (1,923) | (872) | (3,435) | (2,500) | — |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | — | — | — | — | — | 66,563,000 |
| Payment of contingent consideration into escrow | — | — | — | (224) | — | — |
| Payment of deferred offering costs | — | — | 0 | — | — | — |
| Payment of contingent consideration into escrow | — | — | 0 | — | — | — |
| Repayment of old term loan | — | — | (44,550) | — | — | — |
| Net cash used in financing activities - continuing operations | (2,850) | (2,384) | — | — | — | — |
| Net cash used in financing activities - discontinued operations | (41) | (280) | — | — | — | — |
| Net cash used in financing activities | (2,891) | (2,664) | (12,116) | 79,569 | 164,433 | 126,339 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 221 | 2,079 | (475) | (116) | 342 | (96) |
| Net change in cash, cash equivalents and restricted cash | (12,181) | (5,148) | 7,127 | (1,163) | 15,782 | (173) |
| Cash, cash equivalents and restricted cash, at the beginning of the period | 26,200 | 31,348 | 24,221 | 25,384 | 9,602 | 9,775 |
| Cash, cash equivalents and restricted cash, at the end of the period | 14,019 | 26,200 | 31,348 | 24,221 | 25,384 | 9,602 |
| Supplemental disclosure of cash flow information: | ||||||
| Cash paid for interest | — | — | — | — | 4,676,000 | 3,593,000 |
| Cash paid for interest | 4,544 | 5,012 | 4,231 | 4,259 | — | — |
| Supplemental disclosure of noncash investing and financing activities: | ||||||
| Issuance of Series D convertible preferred stock for 2018 Convertible Notes and 2019 Convertible Notes | — | — | — | — | — | 68,476,000 |
| Issuance of Series D convertible preferred stock for Biotronik asset purchase | — | — | — | 0 | 5,000 | — |
| Issuance of Series D convertible preferred stock for Rhythm Xience Acquisition | — | — | — | 0 | 2,197 | — |
| Change in unrealized (gain) loss on marketable securities | — | — | — | — | 53,000 | (46,000) |
| Changes between assets and liabilities in discontinued operations | 0 | 5,445 | — | — | — | — |
| Accounts receivable from sale of business | 1,838 | 9,360 | 17,000 | — | — | — |
| Change in unrealized (gain) loss on marketable securities | 0 | (7) | (39) | 37 | — | — |
| Right-of-use assets exchanged for operating lease liabilities | — | — | 0 | 3,527 | — | 2,978 |
| Accrued purchase of research and development-license | — | — | — | — | — | 5,000,000 |
| Accrued licensed intangibles assets | — | — | — | 0 | 2,000 | — |
| Unpaid purchases of property and equipment | — | — | — | — | 101,000 | 174,000 |
| Transfer of property and equipment to inventory | — | — | — | — | 643,000 | — |
| Change in unpaid purchases of property and equipment | — | 0 | 54 | 124 | — | — |
| Unpaid deferred offering costs | — | — | — | 0 | — | — |
| Contingent consideration escrow release | — | 0 | 381 | — | — | — |
| Net book value on AcQMap system sales-type leases | — | 0 | 244 | 1,104 | — | — |
| Conversion of convertible preferred stock into common stock upon IPO | — | — | — | 0 | 260,555 | — |
| Reclassification of warrant liability to stockholders' equity | — | — | — | — | 14,474,000 | — |
| Reclassification of warrant liability to additional paid-in capital | — | — | — | 0 | — | — |
| Amount of debt proceeds allocated to warrant liability | — | 0 | 3,379 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.